Gibson Dunn Advises Polaryx Therapeutics on Direct Listing on The Nasdaq Capital Market
Firm News | February 4, 2026
Gibson Dunn represented Polaryx Therapeutics, Inc. in connection with its direct listing of shares of common stock on The Nasdaq Capital Market, where shares began trading under the ticker symbol “PLYX” on February 2, 2026.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Polaryx was founded in 2014 and is headquartered in Paramus, New Jersey.
Gibson Dunn regularly advises life sciences companies on direct listings, IPOs, and other capital markets transactions.
The Gibson Dunn corporate team included Ryan Murr, Melanie Neary, Jasmine Vitug, and Risa Nakagawa. Additional team members included Aaron Briggs and Gina Hancock (Executive Compensation/Benefits).